The Relationship of Sevoflurane Consumption With Metabolic Age

August 25, 2023 updated by: DUYGU DEMİROZ, Inonu University
The aim of this clinical study is to determine the consumption of sevoflurane, which is one of the inhalation anesthetics, with metabolic age and basal metabolic rate. The basal metabolic rates and metabolic ages of the patients who will be given sevoflurane- maintained general anesthesia were measured preoperatively. The relationship between the amount of sevoflurane consumption and the measured data of the patients in the postoperative period was examined.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Standard monitoring, BIS, TOF (train of four) were performed from the premedication application. Aspect A 2000 (Aspect Medical Systems, Newton) monitor and single-chip BIS electrodes will be used for BIS. The total amount of sevoflurane consumed and MAK values of these components will be recorded. Chronological age, metabolic age, BMR, height, weight, ideal body weight, BMI, body adiposity, body fluid ratio, body fluid care, fat mass, lean body weight, muscle registered, visceral adiposity, obesity degree in the preoperative period of the patients. Values, ASA scores and demographic data will be recorded for the operation process, cutting time, anesthesia time, extubation time, total sevoflurane consumption throughout the case, and the relationship with basal metabolism and metabolic age will be evaluated.

Study Type

Observational

Enrollment (Actual)

79

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Malatya, Turkey, 44050
        • inonu universitesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

18-65 AGE

Description

Inclusion Criteria:

Between the ages of 18-65 who are scheduled for rhinoplasty or septoplasty with ASA I-II Cases lasting 1 to 3 hours

Exclude Criteria:

Patients at high risk of malignant hyperthermia, with a history of allergy to general anesthesia or any of the drugs to be used in the study, accepted as ASA III- ASA IV

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
percent age difference < -6.6%

The percentage age difference in the negative direction represents patients whose metabolic age is greater than their chronological age.

When we analyze the ROC analysis in the negative direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percentage age difference is -6,6%.

This group refers to those whose percentage age difference is less than -6.6%
Drug: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
Other Names:
  • No procedure was performed on the patient other than routine anesthesia management.
percent age difference -6.6% to 11.7% those between

When we analyze the ROC analysis in the negative direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percentage age difference is -6,6%. When we analyze the ROC analysis in the positive direction, the cut-off value of the percent age difference is 11.7%.

This group refers to those whose percentage age difference between -6.6% and 11.7%
Drug: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
Other Names:
  • No procedure was performed on the patient other than routine anesthesia management.
percent age difference > 11.7%

the percent age difference in the positive direction represents patients whose metabolic age is less than their chronological age.

When we analyze the ROC analysis in the positive direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percent age difference is 11.7%.

This group refers to those whose percentage age difference is more than 11.7%
Drug: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
Other Names:
  • No procedure was performed on the patient other than routine anesthesia management.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
consumption of sevoflurane
Time Frame: patients during surgery
Reducing patients' consumption of sevoflurane according to metabolic law
patients during surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Inonu University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 9, 2022

Primary Completion (Actual)

March 1, 2023

Study Completion (Actual)

March 3, 2023

Study Registration Dates

First Submitted

August 9, 2023

First Submitted That Met QC Criteria

August 25, 2023

First Posted (Actual)

August 30, 2023

Study Record Updates

Last Update Posted (Actual)

August 30, 2023

Last Update Submitted That Met QC Criteria

August 25, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Inonu 2022/92

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sevoflurane

Clinical Trials on Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe